Clinical trial
Anti-CD20 in Systemic Lupus Erythematosus
NCT00036491 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00036491 |
|---|---|
| Title | Anti-CD20 in Systemic Lupus Erythematosus |
| Official title | An Open-Label Safety and Efficacy Study of an Anti-CD20 Antibody (Rituximab, Rituxan®) for Anti-B Cell Therapy in the Treatment of Systemic Lupus Erythematosus |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Autoimmunity Centers of Excellence |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lupus Erythematosus, Systemic |
| Intervention type | Drug |
| Interventions | Rituximab |
| Enrollment | 24 |
| Start date | Jan 1, 2001 |
| Primary completion | Jan 1, 2006 |
| Completion | Jan 1, 2006 |
| First posted | May 13, 2002 |
| Last update posted | Nov 6, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: